|
|
| Line 1: |
Line 1: |
| {{Drugbox|
| | #REDIRECT [[Pegylated interferon alfa-2a]] |
| |IUPAC_name =
| |
| | image =
| |
| | CAS_number=215647-85-1
| |
| | ATC_prefix=L03
| |
| | ATC_suffix=AB11
| |
| | ATC_supplemental=
| |
| | PubChem=
| |
| | DrugBank=BTD00043
| |
| | chemical_formula =
| |
| | molecular_weight = ?
| |
| | bioavailability= ?
| |
| | metabolism = ?
| |
| | elimination_half-life=?
| |
| | excretion = ?
| |
| | pregnancy_category = ?
| |
| | legal_status = ?
| |
| | routes_of_administration= ?
| |
| }}
| |
| | |
| | |
| '''Pegylated interferon alfa-2a''' (40kD) (commercial name '''PEGASYS''') is an [[antiviral]] drug discovered at the pharmaceutical company [[Hoffmann-La Roche|F.Hoffmann-La Roche]]; it has a dual mode of action - both antiviral and on the immune system.
| |
| | |
| This drug is approved around the world for the treatment of chronic [[hepatitis C]] (including patients with [[HIV]] co-infection, [[cirrhosis]], 'normal' levels of [[Alanine transaminase|ALT]]) and has recently been approved (in the [[EU]], [[United States|U.S.]], [[China]] and many other countries) for the treatment of chronic [[hepatitis B]].
| |
| | |
| ==See also==
| |
| * [[Interferon]]
| |
| * [[PEGylation]]
| |
| | |
| ==External links==
| |
| *[http://www.pegasys.com/about-pegasys/pegasys-interferon.aspx/ Interferon and hepatitis c at pegasys.com]
| |
| * [http://www.pmprb-cepmb.gc.ca/english/View.asp?x=324&mp=117 PMPRB at pmprb-cepmb.gc.ca]
| |
| * [http://www.hepalife.com/HCV/Images/HC%20019a.gif Chemical structure at hepalife.com]
| |
| * {{MeshName|Pegasys}}
| |
| | |
| {{pharma-stub}}
| |
| {{Interferons}}
| |
| | |
| [[de:Peginterferon alfa-2a]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WS}}
| |